<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background:Greater <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">adiposity</z:e> and height have been associated with increased risk of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Associations for disease subtypes are uncertain.Methods:A cohort of 1.3 million middle-aged UK women was recruited in 1996-2001 and followed for 10 years on average </plain></SENT>
<SENT sid="2" pm="."><plain>Potential risk factors were assessed by questionnaire </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0011420'>Death</z:hpo>, emigration, and incident <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> were ascertained by linkage to national registers </plain></SENT>
<SENT sid="4" pm="."><plain>Adjusted relative risks were estimated by Cox regression.Results:During follow-up, 9162 participants were diagnosed with lymphatic or haematopoietic <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Each 10 kg m(-2) increase in body mass index was associated with relative risk of 1.20 (95% confidence interval: 1.13-1.28) for lymphoid and 1.37 (1.22-1.53) for <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancy</z:e> (P=0.06 for <z:hpo ids='HP_0001425'>heterogeneity</z:hpo>); similarly, Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> 1.64 (1.21-2.21), diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> 1.36 (1.17-1.58), plasma cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> 1.21 (1.06-1.39), <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> 1.47 (1.19-1.81), and myeloproliferative/<z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> 1.32 (1.15-1.52) </plain></SENT>
<SENT sid="6" pm="."><plain>Each 10 cm increase in height was associated with relative risk of 1.21 (1.16-1.27) for lymphoid and 1.11 (1.02-1.21) for <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancy</z:e> (P=0.07 for <z:hpo ids='HP_0001425'>heterogeneity</z:hpo>); similarly, mature T-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> 1.36 (1.03-1.79), diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> 1.28 (1.14-1.43), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> 1.28 (1.13-1.44), plasma cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> 1.12 (1.01-1.24), <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> 1.23 (1.08-1.40), and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> 1.22 (1.04-1.42) </plain></SENT>
<SENT sid="7" pm="."><plain>There was no significant <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> between subtypes.Conclusion:In middle-aged women, greater body mass index and height were associated with modestly increased risks of many subtypes of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancy</z:e> </plain></SENT>
</text></document>